Barbara Emily Bierer, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ethics Committees, Research | 15 | 2024 | 197 | 5.170 |
Why?
|
Clinical Trials as Topic | 26 | 2024 | 8055 | 2.890 |
Why?
|
Biomedical Research | 21 | 2024 | 3416 | 2.800 |
Why?
|
Information Dissemination | 13 | 2024 | 1132 | 2.080 |
Why?
|
Research Subjects | 8 | 2024 | 249 | 2.050 |
Why?
|
T-Lymphocytes | 66 | 2006 | 10181 | 1.870 |
Why?
|
Ethics, Research | 7 | 2022 | 178 | 1.650 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 27 | 1994 | 900 | 1.490 |
Why?
|
Patient Selection | 9 | 2024 | 4269 | 1.450 |
Why?
|
Authorship | 3 | 2019 | 281 | 1.450 |
Why?
|
Informed Consent | 7 | 2023 | 1008 | 1.410 |
Why?
|
Scientific Misconduct | 2 | 2024 | 74 | 1.330 |
Why?
|
Patient Participation | 4 | 2023 | 1437 | 1.330 |
Why?
|
Tacrolimus | 32 | 2003 | 730 | 1.280 |
Why?
|
Lymphocyte Activation | 44 | 2003 | 5497 | 1.240 |
Why?
|
Confidentiality | 7 | 2024 | 610 | 1.230 |
Why?
|
Polyenes | 21 | 1996 | 68 | 1.080 |
Why?
|
Cyclosporine | 21 | 2003 | 778 | 1.030 |
Why?
|
Research Design | 9 | 2023 | 6168 | 1.000 |
Why?
|
Human Experimentation | 2 | 2017 | 126 | 1.000 |
Why?
|
Receptors, Immunologic | 20 | 1994 | 1434 | 0.980 |
Why?
|
Acupuncture Therapy | 3 | 2024 | 480 | 0.910 |
Why?
|
Ethics Committees | 1 | 2023 | 52 | 0.890 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2023 | 26 | 0.850 |
Why?
|
Delphi Technique | 2 | 2023 | 818 | 0.850 |
Why?
|
Disabled Persons | 2 | 2022 | 1226 | 0.840 |
Why?
|
Federal Government | 1 | 2024 | 267 | 0.820 |
Why?
|
Behavioral Research | 1 | 2022 | 52 | 0.800 |
Why?
|
Clinical Protocols | 2 | 2020 | 1438 | 0.800 |
Why?
|
Ethical Review | 2 | 2019 | 27 | 0.800 |
Why?
|
Phosphoprotein Phosphatases | 15 | 1996 | 330 | 0.760 |
Why?
|
Civil Rights | 1 | 2022 | 131 | 0.730 |
Why?
|
Achievement | 1 | 2022 | 289 | 0.720 |
Why?
|
Calcineurin | 17 | 2003 | 229 | 0.720 |
Why?
|
Immunosuppressive Agents | 22 | 2005 | 4168 | 0.720 |
Why?
|
Privacy | 2 | 2024 | 233 | 0.700 |
Why?
|
Compensation and Redress | 1 | 2019 | 66 | 0.670 |
Why?
|
Journalism, Medical | 1 | 2020 | 73 | 0.670 |
Why?
|
Calmodulin-Binding Proteins | 14 | 1996 | 232 | 0.660 |
Why?
|
Disclosure | 3 | 2023 | 738 | 0.660 |
Why?
|
Triage | 2 | 2023 | 982 | 0.650 |
Why?
|
Antigens, CD | 22 | 2001 | 4000 | 0.640 |
Why?
|
Truth Disclosure | 1 | 2023 | 432 | 0.640 |
Why?
|
Pandemics | 7 | 2024 | 8609 | 0.640 |
Why?
|
Government Regulation | 4 | 2018 | 526 | 0.630 |
Why?
|
Actins | 5 | 2006 | 2048 | 0.630 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2020 | 786 | 0.620 |
Why?
|
Editorial Policies | 2 | 2020 | 457 | 0.620 |
Why?
|
Motivation | 5 | 2020 | 1991 | 0.600 |
Why?
|
Dental Care | 1 | 2021 | 278 | 0.600 |
Why?
|
Humans | 194 | 2024 | 759255 | 0.600 |
Why?
|
Ecosystem | 1 | 2022 | 488 | 0.590 |
Why?
|
Membrane Glycoproteins | 16 | 1999 | 3730 | 0.590 |
Why?
|
Attitude | 1 | 2022 | 777 | 0.590 |
Why?
|
Clinical Competence | 3 | 2022 | 4776 | 0.590 |
Why?
|
Social Values | 1 | 2018 | 225 | 0.590 |
Why?
|
Universal Precautions | 1 | 2017 | 34 | 0.590 |
Why?
|
Jurkat Cells | 13 | 2006 | 736 | 0.560 |
Why?
|
Phlebotomy | 1 | 2017 | 137 | 0.550 |
Why?
|
Antigens, Surface | 13 | 1991 | 1616 | 0.540 |
Why?
|
Morals | 4 | 2022 | 289 | 0.540 |
Why?
|
Receptors, Antigen, T-Cell | 20 | 2001 | 2535 | 0.510 |
Why?
|
Consent Forms | 3 | 2021 | 55 | 0.490 |
Why?
|
Interleukin-2 | 28 | 2006 | 1890 | 0.490 |
Why?
|
Databases, Factual | 4 | 2023 | 8000 | 0.480 |
Why?
|
Facility Regulation and Control | 1 | 2014 | 24 | 0.480 |
Why?
|
Duty to Warn | 1 | 2014 | 31 | 0.480 |
Why?
|
United States Public Health Service | 1 | 2014 | 32 | 0.470 |
Why?
|
Information Storage and Retrieval | 2 | 2020 | 821 | 0.470 |
Why?
|
Vulnerable Populations | 1 | 2020 | 696 | 0.470 |
Why?
|
Signal Transduction | 32 | 2003 | 23362 | 0.460 |
Why?
|
Registries | 4 | 2023 | 8434 | 0.460 |
Why?
|
Publishing | 3 | 2024 | 837 | 0.460 |
Why?
|
Information Systems | 1 | 2016 | 398 | 0.460 |
Why?
|
Rare Diseases | 1 | 2019 | 619 | 0.450 |
Why?
|
Tacrolimus Binding Proteins | 16 | 2002 | 193 | 0.450 |
Why?
|
Nuclear Proteins | 9 | 2002 | 5793 | 0.450 |
Why?
|
Receptors, CXCR4 | 3 | 2003 | 730 | 0.450 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1719 | 0.440 |
Why?
|
Decision Making | 4 | 2022 | 3920 | 0.440 |
Why?
|
Travel | 1 | 2019 | 786 | 0.440 |
Why?
|
Gelsolin | 2 | 2006 | 189 | 0.440 |
Why?
|
Carrier Proteins | 18 | 2003 | 4939 | 0.430 |
Why?
|
Membrane Microdomains | 2 | 2006 | 206 | 0.420 |
Why?
|
Phosphotyrosine | 6 | 2006 | 456 | 0.420 |
Why?
|
Antigens, Differentiation | 9 | 1999 | 913 | 0.420 |
Why?
|
Heat-Shock Proteins | 11 | 1996 | 796 | 0.420 |
Why?
|
Language | 2 | 2021 | 1525 | 0.420 |
Why?
|
Leadership | 1 | 2022 | 1368 | 0.410 |
Why?
|
Cyclic AMP | 6 | 2002 | 1456 | 0.400 |
Why?
|
Data Collection | 1 | 2021 | 3317 | 0.400 |
Why?
|
Patient Advocacy | 1 | 2014 | 358 | 0.390 |
Why?
|
Tetradecanoylphorbol Acetate | 10 | 2003 | 819 | 0.390 |
Why?
|
Hybridomas | 15 | 2002 | 442 | 0.380 |
Why?
|
Organizational Innovation | 1 | 2014 | 535 | 0.380 |
Why?
|
Advisory Committees | 2 | 2017 | 788 | 0.370 |
Why?
|
Conflict of Interest | 2 | 2015 | 549 | 0.360 |
Why?
|
Communication | 2 | 2022 | 3846 | 0.360 |
Why?
|
Curriculum | 2 | 2022 | 3711 | 0.360 |
Why?
|
Research Support as Topic | 3 | 2021 | 699 | 0.360 |
Why?
|
United States | 21 | 2024 | 72237 | 0.340 |
Why?
|
Microtubule-Associated Proteins | 3 | 2000 | 1078 | 0.340 |
Why?
|
Nurse Clinicians | 1 | 2009 | 30 | 0.330 |
Why?
|
Trust | 1 | 2014 | 523 | 0.330 |
Why?
|
Bone Marrow Transplantation | 13 | 2005 | 2696 | 0.330 |
Why?
|
DNA-Binding Proteins | 15 | 2002 | 9590 | 0.310 |
Why?
|
Sirolimus | 22 | 2005 | 1548 | 0.310 |
Why?
|
Protein-Tyrosine Kinases | 9 | 2003 | 2416 | 0.300 |
Why?
|
Program Development | 1 | 2014 | 1295 | 0.300 |
Why?
|
Policy | 3 | 2023 | 511 | 0.300 |
Why?
|
Consensus | 3 | 2023 | 3095 | 0.300 |
Why?
|
NFATC Transcription Factors | 8 | 2006 | 381 | 0.290 |
Why?
|
Computer Security | 2 | 2020 | 260 | 0.290 |
Why?
|
Cancer Care Facilities | 2 | 2009 | 424 | 0.280 |
Why?
|
Microtubules | 4 | 2000 | 1072 | 0.270 |
Why?
|
Cytoskeleton | 4 | 2006 | 1167 | 0.270 |
Why?
|
Transfection | 15 | 2003 | 5783 | 0.270 |
Why?
|
Universities | 1 | 2011 | 980 | 0.260 |
Why?
|
T-Lymphocytes, Cytotoxic | 8 | 1994 | 1765 | 0.260 |
Why?
|
Risk Management | 1 | 2009 | 559 | 0.260 |
Why?
|
Models, Theoretical | 2 | 2014 | 3556 | 0.250 |
Why?
|
Financing, Organized | 2 | 2019 | 204 | 0.250 |
Why?
|
Tyrosine | 6 | 2001 | 1440 | 0.250 |
Why?
|
Research Personnel | 5 | 2024 | 582 | 0.250 |
Why?
|
Amino Acid Isomerases | 6 | 1995 | 31 | 0.240 |
Why?
|
United States Office of Research Integrity | 1 | 2024 | 9 | 0.240 |
Why?
|
Hot Flashes | 2 | 2024 | 327 | 0.230 |
Why?
|
Calcium | 11 | 2003 | 5721 | 0.230 |
Why?
|
Educational Status | 2 | 2022 | 2511 | 0.230 | |